Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer [0.03%]
用于转移性乳腺癌患者的CDK4/6抑制剂减量治疗后的总生存期
Andreas Bjerrum,Andreas Frederik Henriksen,Ann Søegaard Knoop et al.
Andreas Bjerrum et al.
Background: Breast cancer is the most common cancer in women, and the first-line treatment for patients with hormone-receptor positive/HER2-negative metastatic breast cancer is CDK4/6 inhibitor plus endocrine therapy. Und...
Metformin may improve the outcome of patients with colorectal cancer and type 2 diabetes mellitus partly through effects on neutrophil extracellular traps [0.03%]
二甲双胍可能通过影响中性粒细胞胞外陷阱等方式改善结直肠癌合并2型糖尿病患者的预后
Akira Saito,Koji Koinuma,Rie Kawashima et al.
Akira Saito et al.
Background: Although metformin reduces the risk of cancer-related mortality in patents with type 2 diabetes, the mechanism of its anti-cancer effects has not been fully understood. ...
Cannabidiol and fluorinated derivative anti-cancer properties against glioblastoma multiforme cell lines, and synergy with imidazotetrazine agents [0.03%]
大麻二酚及其氟化衍生物对多形性胶质母细胞瘤的抗肿瘤活性及其与咪唑四嗪类药物的协同作用研究
Alice Brookes,Nicholas Kindon,David J Scurr et al.
Alice Brookes et al.
Background: Glioblastoma multiforme (GBM) is an aggressive cancer with poor prognosis, partly due to resistance to the standard chemotherapy treatment, temozolomide (TMZ). Phytocannabinoid cannabidiol (CBD) has exhibited ...
UK recommendations for the management of transgender and gender-diverse patients with inherited cancer risks [0.03%]
英国关于遗传性癌症风险 transgender 和性别多样化患者的管理推荐意见
Josephine Giblin,Beth Coad,Catherine Lamb et al.
Josephine Giblin et al.
As the rate of people openly identifying as transgender or gender diverse (TGD) is increasing, UK cancer genetics services are seeing growing numbers of TGD patients. Lack of appropriate clinical guidelines and a scarcity of robust data abo...
Kevin Shieh,Elizabeth Brem
Kevin Shieh
Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is associated with a poor prognosis, with a median overall survival of approximately five months [1]. The risk for CNS disease has been estimated to be about 5% o...
Comparative efficacy of combined CTLA-4 and PD-1 blockade vs. PD-1 monotherapy in metastatic melanoma: a real-world study [0.03%]
抗CTLA-4与抗PD-1联合治疗相比单用抗PD-1治疗转移性黑色素瘤的疗效：一项真实世界研究
Avital Klein-Brill,Shlomit Amar-Farkash,Keren Rosenberg-Katz et al.
Avital Klein-Brill et al.
Background: In light of the substantial toxicity associated with combined CTLA-4 and PD-1 blockade (ipilimumab and nivolumab), we assessed its efficacy and safety against anti-PD-1 monotherapy (nivolumab or pembrolizumab)...
David Robert Grimes
David Robert Grimes
High-quality cancer research is crucial to both save lives and improve quality of life. Spurious findings, however, impedes these laudable goals by misleading research efforts and creating research waste that is inherently difficult to coun...
Elizabeth Xu,Quan Ho,Ashley Liu et al.
Elizabeth Xu et al.
Background: Neurolymphomatosis is a lymphoid malignancy of the peripheral nervous system and its natural history is poorly understood. Methods: ...
Nay My Oo,Catherine S Weadick,Lucy Murphy et al.
Nay My Oo et al.
Background: Climate change is a threat to human health; equally health care is a threat to climate change as it accounts for 4% of greenhouse gas emissions and 30% of the world's electronically stored data. 350,000 intern...
PTEN pathogenic variants are associated with poor prognosis in patients with advanced soft tissue sarcoma [0.03%]
PTEN致病性变异与晚期软组织肉瘤患者预后不良有关
Minggui Pan,Maggie Y Zhou,Chen Jiang et al.
Minggui Pan et al.
Background: We aimed to examine whether PTEN pathogenic variants (mutPTEN) were associated with overall survival (OS) in patients with advanced soft tissue sarcoma (STS) with the presence of one or more of the most common...